Clinical trials: High-Risk Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
This phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04457596
- Testing
- Trastuzumab Emtansine, Tucatinib, Questionnaire Administration
- Where
- 1,176 sites in United States, Canada and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Lymphocytic Leukemia
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.
- Trial name
- NCT03328273
- Testing
- Ceralasertib, Acalabrutinib
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Prostate Cancer
ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Trial name
- ABRUPT (NCT04831983)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who…
- Trial name
- NCT02775903
- Testing
- Azacitidine, Durvalumab
- Where
- 103 sites in United States, Austria and 10 more
- Volunteers
- 213 people
- Sponsor
- Celgene
Prostate Cancer, Oligometastatic Disease
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of…
- Trial name
- KNIGHTS (NCT06212583)
- Testing
- niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Cirrhosis, Cirrhosis Due to Hepatitis B
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
- Conditions
- Cirrhosis, Cirrhosis Due to Hepatitis B, Cirrhosis and Chronic Liver Disease, Cirrhosis Due to Hepatitis C
- Trial name
- AMULET (NCT06658782)
- Testing
- non contrast enhanced MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Rectal Cancer
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
This study aims to evaluate the effectiveness and safety of combining moderately hypofractionated radiotherapy with chemotherapy and anti-PD-1 antibodies as a neoadjuvant treatment for high-risk locally advanced rectal cancer.
- Trial name
- iMHRT-LARC (NCT06599827)
- Testing
- moderately hypofractionated radiotherapy, chemotherapy, immunotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Cancer, Chronic Myelomonocytic Leukemia
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Study and Dose Rationale The safety profile of clofarabine appears acceptable within the target populations studied to date in the clinical studies summarized in Section 2.3.
- Trial name
- NCT00708721
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Locally Advanced Breast Cancer, Breast Cancer
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca
Women with breast cancer undergo treatments that decrease the chance of recurrence of cancer, but are associated with several side effects, including declines in memory and attention and other thinking abilities.
- Trial name
- Cyto-Cog (NCT00756132)
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer.
- Conditions
- Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma
- Trial name
- NCT00004221
- Testing
- Carboplatin, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Neuroblastoma
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for…
- Trial name
- NCT04936529
- Testing
- β-glucan, GM-CSF, OPT-821
- Where
- United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pharynx Cancer, Larynx Cancer
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
Randomized multicenter trial to assess the impact of a screening program for heavy alcohol drinkers and smokers treated in alcohol addiction clinics on upper aerodigestive tract cancer mortality.
- Conditions
- Pharynx Cancer, Larynx Cancer, Oral Cavity Cancer, Oesophageal Cancer
- Trial name
- NCT00359645
- Testing
- Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years
- Where
- 35 sites in France
- Volunteers
- 1,993 people, healthy volunteers welcome
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Ovarian Cancer
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
To assess alterations of EGFR\& Her2neu expression in primary ovarian high grade serous carcinoma and its correlation with other clinicopathological parameters
- Trial name
- NCT04284631
- Volunteers
- 54 people
- Sponsor
- Port Said University hospital
Anal Neoplasm
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically…
- Trial name
- NCT03499795
- Testing
- VGX-3100, CELLECTRA™ 5PSP
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Inovio Pharmaceuticals
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In patients who have exhausted SoC treatment…
- Trial name
- NCT06416436
- Testing
- Atezolizumab, Stereotactic Ablative Radiotherapy (SBRT)
- Where
- United States
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.